Sasaki A, Nishiyama A, Alcalde R E, Lim D J, Mese H, Nakayama S, Yokoyama S, Matsumura T
Department of Oral and Maxillofacial Surgery II, Okayama University Dental School, Japan.
Oral Oncol. 1999 Sep;35(5):523-9. doi: 10.1016/s1368-8375(99)00027-5.
The mechanism of osteolysis associated with metastatic cancer of the jaws is essentially osteoclast-mediated. Therefore, it is likely that potent osteoclastic bone resorption inhibitors such as bisphosphonates would be efficacious for the treatment of jaw metastasis. We examined the effects of a third generation bisphosphonate, YM175, in a nude mice jaw metastasis model with intracardiac injection of a human breast cancer cell line, MDA-MB-231. The metastatic lesions in untreated mice were radiographically observed at the body and angle of the mandible. Histology of the mandible of untreated mice revealed that most of the bone marrow cavities had been occupied by the metastatic tumor with active osteoclasts along the trabecular bone. The experimental group showed that YM175 markedly reduced the size of tumor and the number of osteoclasts. These results suggest that YM175 may suppress metastasis formation and tumor growth in jaw through inhibition of osteoclastic bone resorption.
与颌骨转移性癌相关的骨溶解机制本质上是破骨细胞介导的。因此,诸如双膦酸盐之类的强效破骨细胞骨吸收抑制剂可能对颌骨转移的治疗有效。我们在心内注射人乳腺癌细胞系MDA-MB-231的裸鼠颌骨转移模型中研究了第三代双膦酸盐YM175的作用。在未治疗小鼠的下颌体和下颌角通过影像学观察到转移性病变。未治疗小鼠下颌骨的组织学检查显示,大多数骨髓腔已被转移性肿瘤占据,沿小梁骨有活跃的破骨细胞。实验组表明,YM175显著减小了肿瘤大小和破骨细胞数量。这些结果表明,YM175可能通过抑制破骨细胞骨吸收来抑制颌骨转移的形成和肿瘤生长。